Joint briefing paper by 7 organisations. The major advance in transparency brought by the adoption of the EU regulation on clinical trials needs to be preserved from neutralisation by industry lobbies.
Joint response by HAI, ISDB and MiEF to a WHO public consultation. The WHO proposal to assign a "biological qualifier" after the International Nonproprietary Name (INN) of glycosylated biosimilars offers an acceptable solution at global level.
Joint response to the EMA consultation by the Cochrane AEMG, HAI Europe, ISDB and MiEF. “Protection of personal data” must not be used as a pretext to strengthen intellectual property over pharmacovigilance data.
In their Joint Response to a consultation by the US Institute of Medicine (IOM), HAI Europe, ISDB, MiEF and TACD encourage the active implementation of a data sharing policy that ensures full public access to clinical data in the US, in alignment with the new European requirements.